Inclusion Criteria
- Participants must have a histologically or cytologically confirmed diagnosis of
Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC
or Stage IV disease.
- Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%.
- Participants must have measurable disease as defined by Response Evaluation Criteria
in Solid Tumors (RECIST) v1.1.
- Participants must have no prior systemic anti-tumor therapy for locally advanced or
metastatic NSCLC.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance
Status 0-1.
Exclusion Criteria
- Participants must not have any documented actionable genomic alteration (AGA) for
which first-line (1L) approved therapies are indicated.
- Participants must not have any symptomatic untreated central nervous system (CNS)
metastases, leptomeningeal metastases (carcinomatous meningitis) or spinal cord
compression.
- Participants must not have any significant cardiovascular impairment as evidenced by
uncontrolled hypertension (despite optimal medical treatment), congestive heart
failure, active coronary disease (within 6 months prior to randomization),
ventricular arrhythmias, or major thrombotic or embolic events or major hemorrhagic
events (within 6 months prior to randomization), or significant risk of pulmonary
hemorrhage.
- Participants must not an active autoimmune disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
